260 related articles for article (PubMed ID: 29615076)
1. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Takahashi K; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M
J Transl Med; 2018 Apr; 16(1):86. PubMed ID: 29615076
[TBL] [Abstract][Full Text] [Related]
2. Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).
Pellegrino B; Tommasi C; Serra O; Gori S; Cretella E; Ambroggi M; Frassoldati A; Bisagni G; Casarini C; Bria E; Carbognin L; Fiorio E; Mura A; Zamagni C; Gianni L; Zambelli A; Montemurro F; Tognetto M; Todeschini R; Missale G; Campanini N; Silini EM; Maglietta G; Musolino A
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38016718
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results.
Andersson M; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Perez EA
Oncologist; 2017 Oct; 22(10):1160-1168. PubMed ID: 28592618
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial.
Ding N; Pang J; Liu X; He X; Zhou W; Xie H; Feng J; Wang G; Tang J; Cao J; He L; He Y; Wang S; Xiao Z
Breast Cancer Res; 2024 Jan; 26(1):9. PubMed ID: 38212845
[TBL] [Abstract][Full Text] [Related]
5. HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results.
Seo J; Koh J; Lee DW; Kim J; Ryu HS; Lee KH; Kim TY; Im SA
Breast Cancer Res; 2023 Dec; 25(1):154. PubMed ID: 38098054
[TBL] [Abstract][Full Text] [Related]
6. Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer Predicted by CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes.
Rustamadji P; Wiyarta E; Pramono M; Maulanisa SC
Asian Pac J Cancer Prev; 2024 May; 25(5):1607-1613. PubMed ID: 38809632
[TBL] [Abstract][Full Text] [Related]
7. Tucatinib promotes immune activation and synergizes with programmed cell death-1 and programmed cell death-ligand 1 inhibition in HER2-positive breast cancer.
Li R; Sant S; Brown E; Caramia F; Nikolic B; Clarke K; Byrne A; Lara Gonzalez LE; Savas P; Luen SJ; Teo ZL; Virassamy B; Neeson PJ; Darcy PK; Loi S
J Natl Cancer Inst; 2023 Jul; 115(7):805-814. PubMed ID: 37166471
[TBL] [Abstract][Full Text] [Related]
8. The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer.
Çetin K; Kökten Ş; Sarıkamış B; Yıldırım S; Gökçe ON; Barışık NÖ; Kılıç Ü
Breast Cancer Res Treat; 2024 May; 205(1):17-27. PubMed ID: 38273215
[TBL] [Abstract][Full Text] [Related]
9. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients.
Sun S; Fei X; Mao Y; Wang X; Garfield DH; Huang O; Wang J; Yuan F; Sun L; Yu Q; Jin X; Wang J; Shen K
Cancer Immunol Immunother; 2014 Apr; 63(4):395-406. PubMed ID: 24514954
[TBL] [Abstract][Full Text] [Related]
10. Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.
Jørgensen N; Hviid TVF; Nielsen LB; Sønderstrup IMH; Eriksen JO; Ejlertsen B; Gerdes AM; Kruse TA; Thomassen M; Jensen MB; Lænkholm AV
Br J Cancer; 2021 Nov; 125(10):1388-1398. PubMed ID: 34365471
[TBL] [Abstract][Full Text] [Related]
11. An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
Fukui R; Watanabe T; Morimoto K; Fujimoto Y; Nagahashi M; Ishikawa E; Hirota S; Miyoshi Y
Breast Cancer; 2023 Sep; 30(5):703-713. PubMed ID: 37115435
[TBL] [Abstract][Full Text] [Related]
12. The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer.
Lee KH; Kim EY; Yun JS; Park YL; Do SI; Chae SW; Park CH
BMC Cancer; 2018 Oct; 18(1):938. PubMed ID: 30285668
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.
Leffers N; Gooden MJ; de Jong RA; Hoogeboom BN; ten Hoor KA; Hollema H; Boezen HM; van der Zee AG; Daemen T; Nijman HW
Cancer Immunol Immunother; 2009 Mar; 58(3):449-59. PubMed ID: 18791714
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer.
Yamamoto K; Makino T; Sato E; Noma T; Urakawa S; Takeoka T; Yamashita K; Saito T; Tanaka K; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Mori M; Doki Y; Wada H
Cancer Sci; 2020 Apr; 111(4):1103-1112. PubMed ID: 31981293
[TBL] [Abstract][Full Text] [Related]
15. Circulating CD8
Lin KR; Pang DM; Jin YB; Hu Q; Pan YM; Cui JH; Chen XP; Lin YX; Mao XF; Duan HB; Luo W
Cancer Immunol Immunother; 2018 Nov; 67(11):1743-1752. PubMed ID: 30167861
[TBL] [Abstract][Full Text] [Related]
16. High CD8
Fluxá P; Rojas-Sepúlveda D; Gleisner MA; Tittarelli A; Villegas P; Tapia L; Rivera MT; López MN; Catán F; Uribe M; Salazar-Onfray F
BMC Cancer; 2018 Mar; 18(1):243. PubMed ID: 29499656
[TBL] [Abstract][Full Text] [Related]
17. Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma.
Pölcher M; Braun M; Friedrichs N; Rudlowski C; Bercht E; Fimmers R; Sauerwald A; Keyver-Paik MD; Kübler K; Büttner R; Kuhn WC; Hernando JJ
Cancer Immunol Immunother; 2010 Jun; 59(6):909-19. PubMed ID: 20087581
[TBL] [Abstract][Full Text] [Related]
18. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
Steenbruggen TG; Wolf DM; Campbell MJ; Sanders J; Cornelissen S; Thijssen B; Salgado RA; Yau C; O-Grady N; Basu A; Bhaskaran R; Mittempergher L; Hirst GL; Coppe JP; Kok M; Sonke GS; van 't Veer LJ; Horlings HM
Breast Cancer Res; 2023 Oct; 25(1):117. PubMed ID: 37794508
[TBL] [Abstract][Full Text] [Related]
19. Radiological Features for Predicting the Status of CD8-Positive Lymphocytes in HER2 Positive Breast Cancer.
Fan Y; Li X; Zhong P; Guo H; Han D; Tian W; Fang J
Balkan Med J; 2024 May; 41(3):213-221. PubMed ID: 38700366
[TBL] [Abstract][Full Text] [Related]
20. Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade.
Batalha S; Gomes CM; Brito C
Front Immunol; 2023; 14():1267621. PubMed ID: 38022643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
